- Article
- Source: Campus Sanofi
Beyfortus®▼ (Nirsevimab)
Beyfortus is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in:
i. Neonates and infants during their first RSV season.
ii. Children up to 24 months of age who remain vulnerable to severe RSV disease through their second season RSV season (see SmPC). Beyfortus should be used in accordance with official recommendations.
Click here for Prescribing Information IE (External Link)
Use the following downloadable resources to support with the administration of Beyfortus
Beyfortus® discussion guide
Download our handy discussion guide to get the most out of your next appointment.
Dosing and administration
Pocket FAQ
Fridge shelf talker
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspect adverse reactions.
Adverse events should be reported. Reporting forms and information can be found at www.hpra.ie; email: medsafety@hpra.ie. Adverse events should also be reported to Sanofi Ireland Ltd. Tel: 01 4013 5600.
Alternatively, send via email to IEPharmacovigilance@sanofi.com
